Hobert Wai is a partner at Black Tiger Capital focusing on the life science and healthcare sectors. He co-founded Black Tiger to invest and partner with innovators to vitalize novel ideas into feasible entrepreneurship. He also co-founded J.A.D.E. (Joint Association to Develop Entrepreneurship) to build sustainable entrepreneurship in Hong Kong and Southeast Asia by elevating the region’s startup ecosystem resiliency through intimate cross-pollination with successful entrepreneurs and capitalists. Previously, he was associate director at Becton Dickinson (BD) in which he was instrumental in driving the clinical business to achieve $1B revenue primarily through new oncology and HIV diagnostic product development. Hobert led multiple teams of scientists and business managers to develop and launch novel system solutions to address the infectious disease and oncology unmet medical needs in both developed and developing markets. He is an expert in agile development, business development, design control, FDA and ISO regulations, and technology development. He has hands-on product registration experience in all continents, excluding Antarctica, with regulatory agencies including FDA, CFDA, EU, and others. Before BD, Hobert worked at Bio-Rad on medical device quality systems and at Beckman Coulter on automated clinical assay, specialty chemistry, cellomics, proteomics, genomics, and laboratory automation systems. He launched 5 in vitro diagnostic (IVD) platforms, 10 IVD assay kits, 22 Analyte Specific Reagents, 8 Research Use Only (RUO) platforms, and 15 RUO assay kits. Dr. Wai’s effort in collaborative science advancement has resulted in numerous peer-reviewed scientific publications and patent issuance. He received an A.B. in Molecular Cell Biology from University of California, Berkeley, Ph.D. in Biological Chemistry from University of California, Irvine, and an MBA from The Wharton School at University of Pennsylvania.